Jump to content Main menu Main menu move to sidebar hide Navigation Main page Contents Current events Random article About Wikipedia Contact us Contribute Help Learn to edit Community portal Recent changes Upload file Special pages Search Search Appearance Donate Create account Log in Personal tools Donate Create account Log in Pages for logged out editors learn more Contributions Talk CentralNotice Contents move to sidebar hide (Top) 1 Discovery 2 Mechanism and pharmacology Toggle Mechanism and pharmacology subsection 2.1 NOP cellular signalling partners 2.2 Neuroanatomy 2.2.1 Pain circuitry 2.2.2 Reward circuitry 3 Therapeutic potential Toggle Therapeutic potential subsection 3.1 Analgesia and abuse liability 3.2 Agonists 3.3 Antagonists 4 Applications 5 References 6 Further reading 7 External links Toggle the table of contents Nociceptin receptor 3 languages Српски / srpski Srpskohrvatski / српскохрватски Українська Edit links Article Talk English Read Edit View history Tools Tools move to sidebar hide Actions Read Edit View history General What links here Related changes Upload file Permanent link Page information Cite this page Get shortened URL Download QR code Print/export Download as PDF Printable version In other projects Wikidata item Appearance move to sidebar hide From Wikipedia, the free encyclopedia Protein-coding gene in the species Homo sapiens OPRL1 Available structures PDB Ortholog search: A0A0G2JQE4 PDBe A0A0G2JQE4 RCSB List of PDB id codes 4EA3 , 5DHG , 5DHH Identifiers Aliases OPRL1 , KOR-3, NOCIR, OOR, ORL1, NOP, NOPr, opioid related nociceptin receptor 1, KOR3, OPRL, PNOCR External IDs OMIM : 602548 ; MGI : 97440 ; HomoloGene : 22609 ; GeneCards : OPRL1 ; OMA : OPRL1 - orthologs Gene location ( Human ) Chr.

Chromosome 20 (human) [ 1 ] Band 20q13.33 Start 64,080,082 bp [ 1 ] End 64,100,643 bp [ 1 ] Gene location ( Mouse ) Chr.

Chromosome 2 (mouse) [ 2 ] Band 2 H4|2 103.74 cM Start 181,356,809 bp [ 2 ] End 181,362,778 bp [ 2 ] RNA expression pattern Bgee Human Mouse (ortholog) Top expressed in blood superior frontal gyrus right frontal lobe Brodmann area 9 white blood cell monocyte granulocyte primary visual cortex nucleus accumbens hypothalamus Top expressed in ventromedial nucleus dorsomedial hypothalamic nucleus paraventricular nucleus of hypothalamus arcuate nucleus lateral hypothalamus ventral tegmental area lumbar subsegment of spinal cord mammillary body dorsal tegmental nucleus anterior amygdaloid area More reference expression data BioGPS n/a Gene ontology Molecular function nociceptin receptor activity neuropeptide binding signal transducer activity G protein-coupled opioid receptor activity protein binding G protein-coupled receptor activity protein C-terminus binding peptide binding Cellular component integral component of membrane membrane plasma membrane integral component of plasma membrane neuron projection cytoplasmic vesicle Biological process response to estradiol adenylate cyclase-inhibiting G protein-coupled receptor signaling pathway sensory perception positive regulation of urine volume eating behavior regulation of sensory perception of pain negative regulation of blood pressure estrous cycle regulation of locomotor rhythm positive regulation of gastric acid secretion positive regulation of sensory perception of pain sensory perception of pain negative regulation of voltage-gated calcium channel activity neuropeptide signaling pathway signal transduction chemical synaptic transmission G protein-coupled receptor signaling pathway animal behavior negative regulation of cAMP-mediated signaling negative regulation of adenylate cyclase-activating G protein-coupled receptor signaling pathway G protein-coupled opioid receptor signaling pathway positive regulation of cytosolic calcium ion concentration involved in phospholipase C-activating G protein-coupled signaling pathway conditioned place preference Sources: Amigo / QuickGO Orthologs Species Human Mouse Entrez 4987 18389 Ensembl ENSG00000277044 ENSG00000125510 ENSMUSG00000027584 UniProt P41146 P35377 RefSeq (mRNA) NM_000913 NM_001200019 NM_182647 NM_001318853 NM_001318854 NM_001318855 NM_001252565 NM_011012 NM_001318919 NM_001318920 NM_001318922 NM_001318923 NM_001318924 NM_001318925 RefSeq (protein) NP_000904 NP_001186948 NP_001305782 NP_001305783 NP_001305784 NP_872588 NP_001239494 NP_001305848 NP_001305849 NP_001305851 NP_001305852 NP_001305853 NP_001305854 NP_035142 Location (UCSC) Chr 20: 64.08 – 64.1 Mb Chr 2: 181.36 – 181.36 Mb PubMed search [ 3 ] [ 4 ] Wikidata View/Edit Human View/Edit Mouse The nociceptin opioid peptide receptor ( NOP ), also known as the nociceptin/orphanin FQ ( N/OFQ ) receptor or kappa-type 3 opioid receptor , is a protein that in humans is encoded by the OPRL1 (opioid receptor-like 1) gene .

[ 5 ] The nociceptin receptor is a member of the opioid subfamily of G protein-coupled receptors whose natural ligand is the 17 amino acid neuropeptide known as nociceptin (N/OFQ) .

[ 6 ] This receptor is involved in the regulation of numerous brain activities, particularly instinctive and emotional behaviors.

[ 7 ] Antagonists targeting NOP are under investigation for their role as treatments for depression and Parkinson's disease, whereas NOP agonists have been shown to act as powerful, non-addictive painkillers in non-human primates.

Although NOP shares high sequence identity (~60%) with the ‘classical’ opioid receptors μ-OP (MOP) , κ-OP (KOP) , and δ-OP (DOP) , it possesses little or no affinity for opioid peptides or morphine-like compounds.

[ 8 ] Likewise, classical opioid receptors possess little affinity towards NOP's endogenous ligand nociceptin, which is structurally related to dynorphin A .

[ 8 ] Discovery [ edit ] In 1994, Mollereau et al. cloned a receptor that was highly homologous to the classical opioid receptors (OPs) μ-OR (MOP) , κ-OR (KOP) , and δ-OR (DOP) that came to be known as the Nociceptin Opioid Peptide receptor (NOP).

[ 9 ] As these “classical” opioid receptors were identified 30 years earlier in the mid-1960s, the physiological and pharmacological characterization of NOP as well as therapeutic development targeting this receptor remain decades behind.

[ 10 ] [ 11 ] Although research on NOP has blossomed into its own sub-field, the lack of widespread knowledge of NOP's existence means that it is commonly omitted from studies that investigate the OP family, despite its promising role as a therapeutic target.

Mechanism and pharmacology [ edit ] Nociceptin receptor vestibule complexed with nociceptin.

[ 12 ] Upper part of TM helix 5 is hidden.

NOP cellular signalling partners [ edit ] Like most G-protein coupled receptors , NOP signals through canonical G proteins upon activation. G proteins are heterotrimeric complexes consisting of α, β, and γ subunits. NOP signals through a variety of Gα subtypes that trigger diverse downstream signaling cascades. NOP coupling to Gα i or Gα o subunits leads to an inhibition of adenylyl cyclase (AC) causing an intracellular decrease in cyclic adenosine monophosphate (cAMP) levels, an important second messenger for many signal transduction pathways.

[ 13 ] [ 14 ] NOP acting through Gα i/o pathways has also been shown to activate Phospholipase A2 (PLA2), thereby initiating Mitogen-activated protein kinase (MAPK) signaling cascades.

[ 15 ] In contrast to classical OPs, NOP also couples to Pertussis toxin (PTX)-insensitive subtypes Gα z , Gα 14 , and Gα 16 , as well as potentially to Gα 12 and Gαs.

[ 16 ] [ 17 ] [ 18 ] Activation of NOP's canonical β-arrestin pathway causes receptor phosphorylation, internalization, and eventual downregulation and recycling.

[ 19 ] [ 20 ] NOP activation also causes indirect inhibition of opioid receptors MOP and KOP, resulting in anti-opioid activity in certain tissues. Additionally, NOP activation leads to the activation of potassium channels and inhibition of calcium channels which collectively inhibit neuronal firing.

[ 21 ] [ 22 ] [ 23 ] Neuroanatomy [ edit ] Nociceptin controls a wide range of biological functions ranging from nociception to food intake, from memory processes to cardiovascular and renal functions, from spontaneous locomotor activity to gastrointestinal motility , from anxiety to the control of neurotransmitter release at peripheral and central sites.

[ 24 ] Pain circuitry [ edit ] The outcome of NOP activation on the brain's pain circuitry is site-specific. Within the central nervous system its action can be either similar or opposite to those of opioids depending on their location.

[ 24 ] In animal models, activation of NOP in the brain stem and higher brain regions has mixed action, resulting in overall anti-opioid activity. NOP activation at the spinal cord and peripheral nervous system results in morphine-comparable analgesia in non-human primates.

Reward circuitry [ edit ] NOP is highly expressed in every node of the mesocorticolimbic reward circuitry. Unlike MOP agonists such as codeine and morphine, NOP agonists do not have reinforcing effects. Nociceptin is thought to be an endogenous antagonist of dopamine transport that may act either directly on dopamine or by inhibiting GABA to affect dopamine levels.

[ 25 ] In animal models, the result of NOP activation in the central nervous system has been shown to eliminate conditioned place preference induced by morphine, cocaine, alcohol, and methamphetamine.

[ 26 ] Therapeutic potential [ edit ] Analgesia and abuse liability [ edit ] Recent studies indicate that targeting NOP is a promising alternative route to relieving pain without the deleterious side effects of traditional MOP-activating opioid therapies.

[ 27 ] [ 28 ] [ 29 ] [ 30 ] [ 31 ] [ 32 ] In primates, specifically activating NOP through systemic or intrathecal administration induces long-lasting, morphine-comparable analgesia without causing itch, respiratory depression, or the reinforcing effects that lead to addiction in an intravenous self-administration paradigm; thus eliminating all of the serious side-effects of current opioid therapies.

[ 32 ] Several commonly used opioid drugs including etorphine and buprenorphine have been demonstrated to bind to nociceptin receptors, but this binding is relatively insignificant compared to their activity at other opioid receptors in the acute setting (however the non-analgesic NOPr antagonist SB-612,111 was demonstrated to potentiate the therapeutic benefits of morphine). Chronic administration of nociceptin receptor agonists results in an attenuation of the analgesic and anti- allodynic effects of opiates; this mechanism inhibits the action of endogenous opioids as well, resulting in an increase in pain severity, depression, and both physical and psychological opiate dependence following chronic NOPr agonist administration.

[ 33 ] Administration of the NOPr antagonist SB-612,111 has been shown to inhibit this process.

[ 34 ] More recently a range of selective ligands for NOP have been developed, which show little or no affinity to other opioid receptors and so allow NOP-mediated responses to be studied in isolation.

Agonists [ edit ] AT-121 (Experimental agonist of both the μ-opioid and nociceptin receptors, showing promising results in non-human primates.) Buprenorphine (partial agonist, not selective for NOP, also partial agonist of μ-opioid receptors, and competitive antagonist of δ-opioid and κ-opioid receptors) BU08028 (Analogue of buprenorphine, partial agonist, agonist of μ-opioid receptor, has analgesic properties without physical dependence.) [ 35 ] Cebranopadol (full agonist at NOP, μ-opioid and δ-opioid receptors, partial agonist at κ-opioid receptor) Etorphine MCOPPB [ 36 ] (full agonist) MT-7716 Nociceptin Norbuprenorphine (full agonist; non-selective (also full agonist at the MOR and DOR and partial agonist at the KOR); peripherally-selective) NNC 63-0532 Ro64-6198 Ro65-6570 SCH-221,510 SR-8993 SR-16435 (mixed MOR / NOP partial agonist) TH-030418 Antagonists [ edit ] AT-076 (non-selective) JTC-801 J-113,397 LY-2940094 SB-612,111 SR-16430 Thienorphine Applications [ edit ] NOP agonists are being studied as treatments for heart failure and migraine [ 37 ] while nociceptin antagonists such as JTC-801 may have analgesic [ 38 ] and antidepressant qualities.

[ 39 ] References [ edit ] ^ a b c ENSG00000125510 GRCh38: Ensembl release 89: ENSG00000277044, ENSG00000125510 – Ensembl , May 2017 ^ a b c GRCm38: Ensembl release 89: ENSMUSG00000027584 – Ensembl , May 2017 ^ "Human PubMed Reference:" .

National Center for Biotechnology Information, U.S. National Library of Medicine .

^ "Mouse PubMed Reference:" .

National Center for Biotechnology Information, U.S. National Library of Medicine .

^ Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. (March 1994).

"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization" .

FEBS Letters .

341 (1): 33– 8.

Bibcode : 1994FEBSL.341...33M .

doi : 10.1016/0014-5793(94)80235-1 .

PMID 8137918 .

S2CID 25491521 .

^ Henderson G, McKnight AT (August 1997). "The orphan opioid receptor and its endogenous ligand--nociceptin/orphanin FQ".

Trends in Pharmacological Sciences .

18 (8): 293– 300.

doi : 10.1016/S0165-6147(97)90645-3 .

PMID 9277133 .

^ "Entrez Gene: OPRL1 opiate receptor-like 1" .

^ a b Butour JL, Moisand C, Mazarguil H, Mollereau C, Meunier JC (February 1997). "Recognition and activation of the opioid receptor-like ORL 1 receptor by nociceptin, nociceptin analogs and opioids".

European Journal of Pharmacology .

321 (1): 97– 103.

doi : 10.1016/S0014-2999(96)00919-3 .

PMID 9083791 .

^ Mollereau C, Parmentier M, Mailleux P, Butour JL, Moisand C, Chalon P, et al. (March 1994).

"ORL1, a novel member of the opioid receptor family. Cloning, functional expression and localization" .

FEBS Letters .

341 (1): 33– 8.

Bibcode : 1994FEBSL.341...33M .

doi : 10.1016/0014-5793(94)80235-1 .

PMID 8137918 .

S2CID 25491521 .

^ Martin WR (December 1967).

"Opioid antagonists" .

Pharmacological Reviews .

19 (4): 463– 521.

PMID 4867058 .

^ Goldstein A, Lowney LI, Pal BK (August 1971).

"Stereospecific and nonspecific interactions of the morphine congener levorphanol in subcellular fractions of mouse brain" .

Proceedings of the National Academy of Sciences of the United States of America .

68 (8): 1742– 7.

Bibcode : 1971PNAS...68.1742G .

doi : 10.1073/pnas.68.8.1742 .

PMC 389284 .

PMID 5288759 .

^ Wang Y, Zhuang Y, DiBerto JF, Zhou XE, Schmitz GP, Yuan Q, et al. (2023).

"Structures of the entire human opioid receptor family" .

Cell .

186 (2): 413–427.e17.

doi : 10.1016/j.cell.2022.12.026 .

PMID 36638794 .

^ Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. (October 1995).

"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor" .

Nature .

377 (6549): 532– 5.

Bibcode : 1995Natur.377..532M .

doi : 10.1038/377532a0 .

PMID 7566152 .

S2CID 4326860 .

^ Reinscheid RK, Nothacker HP, Bourson A, Ardati A, Henningsen RA, Bunzow JR, et al. (1995). "Orphanin FQ: a neuropeptide that activates an opioidlike G protein-coupled receptor".

Science .

270 (5237): 792– 4.

Bibcode : 1995Sci...270..792R .

doi : 10.1126/science.270.5237.792 .

PMID 7481766 .

S2CID 38117854 .

^ Fukuda K, Shoda T, Morikawa H, Kato S, Mima H, Mori K (1998).

"Activation of phospholipase A2 by the nociceptin receptor expressed in Chinese hamster ovary cells" .

Journal of Neurochemistry .

71 (5): 2186– 92.

doi : 10.1046/j.1471-4159.1998.71052186.x .

PMID 9798946 .

S2CID 22919153 .

^ Childers SR, Snyder SH (1978). "Guanine nucleotides differentiate agonist and antagonist interactions with opiate receptors".

Life Sciences .

23 (7): 759– 61.

doi : 10.1016/0024-3205(78)90077-2 .

PMID 211364 .

^ Chan JS, Yung LY, Lee JW, Wu YL, Pei G, Wong YH (1998).

"Pertussis toxin-insensitive signaling of the ORL1 receptor: coupling to Gz and G16 proteins" .

Journal of Neurochemistry .

71 (5): 2203– 10.

doi : 10.1046/j.1471-4159.1998.71052203.x .

PMID 9798948 .

S2CID 7978426 .

^ Yung LY, Joshi SA, Chan RY, Chan JS, Pei G, Wong YH (January 1999).

"GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C" .

The Journal of Pharmacology and Experimental Therapeutics .

288 (1): 232– 8.

PMID 9862775 .

^ Dhawan BN, Cesselin F, Raghubir R, Reisine T, Bradley PB, Portoghese PS, et al. (December 1996). "International Union of Pharmacology. XII. Classification of opioid receptors".

Pharmacological Reviews .

48 (4): 567– 92.

PMID 8981566 .

^ Donica CL, Awwad HO, Thakker DR, Standifer KM (May 2013).

"Cellular mechanisms of nociceptin/orphanin FQ (N/OFQ) peptide (NOP) receptor regulation and heterologous regulation by N/OFQ" .

Molecular Pharmacology .

83 (5): 907– 18.

doi : 10.1124/mol.112.084632 .

PMC 3629824 .

PMID 23395957 .

^ Connor M, Yeo A, Henderson G (1996).

"The effect of nociceptin on Ca2+ channel current and intracellular Ca2+ in the SH-SY5Y human neuroblastoma cell line" .

British Journal of Pharmacology .

118 (2): 205– 7.

doi : 10.1111/j.1476-5381.1996.tb15387.x .

PMC 1909632 .

PMID 8735615 .

^ Connor M, Vaughan CW, Chieng B, Christie MJ (1996).

"Nociceptin receptor coupling to a potassium conductance in rat locus coeruleus neurones in vitro" .

British Journal of Pharmacology .

119 (8): 1614– 8.

doi : 10.1111/j.1476-5381.1996.tb16080.x .

PMC 1915781 .

PMID 8982509 .

^ Ikeda K, Kobayashi T, Kumanishi T, Niki H, Yano R (2000). "Involvement of G-protein-activated inwardly rectifying K (GIRK) channels in opioid-induced analgesia".

Neuroscience Research .

38 (1): 113– 6.

doi : 10.1016/S0168-0102(00)00144-9 .

PMID 10997585 .

S2CID 29108127 .

^ a b Calo' G, Guerrini R, Rizzi A, Salvadori S, Regoli D (April 2000).

"Pharmacology of nociceptin and its receptor: a novel therapeutic target" .

British Journal of Pharmacology .

129 (7): 1261– 83.

doi : 10.1038/sj.bjp.0703219 .

PMC 1571975 .

PMID 10742280 .

^ Liu Z, Wang Y, Zhang J, Ding J, Guo L, Cui D, et al. (March 2001). "Orphanin FQ: an endogenous antagonist of rat brain dopamine transporter".

NeuroReport .

12 (4): 699– 702.

doi : 10.1097/00001756-200103260-00017 .

PMID 11277567 .

S2CID 27631391 .

^ Toll L, Bruchas MR, Calo' G, Cox BM, Zaveri NT (April 2016).

"Nociceptin/Orphanin FQ Receptor Structure, Signaling, Ligands, Functions, and Interactions with Opioid Systems" .

Pharmacological Reviews .

68 (2): 419– 57.

doi : 10.1124/pr.114.009209 .

PMC 4813427 .

PMID 26956246 .

^ Lin AP, Ko MC (February 2013).

"The therapeutic potential of nociceptin/orphanin FQ receptor agonists as analgesics without abuse liability" .

ACS Chemical Neuroscience .

4 (2): 214– 24.

doi : 10.1021/cn300124f .

PMC 3582300 .

PMID 23421672 .

^ Sukhtankar DD, Zaveri NT, Husbands SM, Ko MC (July 2013).

"Effects of spinally administered bifunctional nociceptin/orphanin FQ peptide receptor/μ-opioid receptor ligands in mouse models of neuropathic and inflammatory pain" .

The Journal of Pharmacology and Experimental Therapeutics .

346 (1): 11– 22.

doi : 10.1124/jpet.113.203984 .

PMC 3684842 .

PMID 23652222 .

^ Hu E, Calò G, Guerrini R, Ko MC (January 2010).

"Long-lasting antinociceptive spinal effects in primates of the novel nociceptin/orphanin FQ receptor agonist UFP-112" .

Pain .

148 (1): 107– 13.

doi : 10.1016/j.pain.2009.10.026 .

PMC 2861283 .

PMID 19945794 .

^ Ko MC, Wei H, Woods JH, Kennedy RT (September 2006). "Effects of intrathecally administered nociceptin/orphanin FQ in monkeys: behavioral and mass spectrometric studies".

The Journal of Pharmacology and Experimental Therapeutics .

318 (3): 1257– 64.

doi : 10.1124/jpet.106.106120 .

PMID 16766718 .

S2CID 9537945 .

^ Ko MC, Naughton NN (May 2009).

"Antinociceptive effects of nociceptin/orphanin FQ administered intrathecally in monkeys" .

The Journal of Pain .

10 (5): 509– 16.

doi : 10.1016/j.jpain.2008.11.006 .

PMC 2797530 .

PMID 19231294 .

^ a b Ko MC, Woods JH, Fantegrossi WE, Galuska CM, Wichmann J, Prinssen EP (August 2009).

"Behavioral effects of a synthetic agonist selective for nociceptin/orphanin FQ peptide receptors in monkeys" .

Neuropsychopharmacology .

34 (9): 2088– 96.

doi : 10.1038/npp.2009.33 .

PMC 2804925 .

PMID 19279568 .

^ Khroyan TV, Polgar WE, Orduna J, Montenegro J, Jiang F, Zaveri NT, et al. (November 2011).

"Differential effects of nociceptin/orphanin FQ (NOP) receptor agonists in acute versus chronic pain: studies with bifunctional NOP/μ receptor agonists in the sciatic nerve ligation chronic pain model in mice" .

The Journal of Pharmacology and Experimental Therapeutics .

339 (2): 687– 93.

doi : 10.1124/jpet.111.184663 .

PMC 3199991 .

PMID 21859931 .

^ Zaratin PF, Petrone G, Sbacchi M, Garnier M, Fossati C, Petrillo P, et al. (February 2004). "Modification of nociception and morphine tolerance by the selective opiate receptor-like orphan receptor antagonist (-)-cis-1-methyl-7-[ [4-(2,6-dichlorophenyl)piperidin-1-yl]methyl]-6,7,8,9-tetrahydro-5H-benzocyclohepten-5-ol (SB-612111)".

The Journal of Pharmacology and Experimental Therapeutics .

308 (2): 454– 61.

doi : 10.1124/jpet.103.055848 .

PMID 14593080 .

S2CID 8036750 .

^ Ding H, Czoty PW, Kiguchi N, Cami-Kobeci G, Sukhtankar DD, Nader MA, et al. (September 2016).

"A novel orvinol analog, BU08028, as a safe opioid analgesic without abuse liability in primates" .

Proceedings of the National Academy of Sciences of the United States of America .

113 (37): E5511–8.

Bibcode : 2016PNAS..113E5511D .

doi : 10.1073/pnas.1605295113 .

PMC 5027459 .

PMID 27573832 .

S2CID 36624494 .

^ Hirao A, Imai A, Sugie Y, Yamada Y, Hayashi S, Toide K (March 2008).

"Pharmacological characterization of the newly synthesized nociceptin/orphanin FQ-receptor agonist 1-[1-(1-methylcyclooctyl)-4-piperidinyl]-2-[(3R)-3-piperidinyl]-1H-benzimidazole as an anxiolytic agent" .

Journal of Pharmacological Sciences .

106 (3): 361– 8.

doi : 10.1254/jphs.fp0071742 .

PMID 18319566 .

^ Mørk H, Hommel K, Uddman R, Edvinsson L, Jensen R (September 2002). "Does nociceptin play a role in pain disorders in man?".

Peptides .

23 (9): 1581– 7.

doi : 10.1016/S0196-9781(02)00101-8 .

PMID 12217418 .

S2CID 22718102 .

^ Scoto GM, Aricò G, Ronsisvalle S, Parenti C (July 2007). "Blockade of the nociceptin/orphanin FQ/NOP receptor system in the rat ventrolateral periaqueductal gray potentiates DAMGO analgesia".

Peptides .

28 (7): 1441– 6.

doi : 10.1016/j.peptides.2007.05.013 .

PMID 17628212 .

S2CID 29027947 .

^ Redrobe JP, Calo' G, Regoli D, Quirion R (February 2002). "Nociceptin receptor antagonists display antidepressant-like properties in the mouse forced swimming test".

Naunyn-Schmiedeberg's Archives of Pharmacology .

365 (2): 164– 7.

doi : 10.1007/s00210-001-0511-0 .

PMID 11819035 .

S2CID 25596953 .

Further reading [ edit ] Mollereau C, Mouledous L (July 2000). "Tissue distribution of the opioid receptor-like (ORL1) receptor".

Peptides .

21 (7): 907– 17.

doi : 10.1016/S0196-9781(00)00227-8 .

PMID 10998524 .

S2CID 13294560 .

New DC, Wong YH (2003).

"The ORL1 receptor: molecular pharmacology and signalling mechanisms" .

Neuro-Signals .

11 (4): 197– 212.

doi : 10.1159/000065432 .

PMID 12393946 .

Zaveri N (June 2003).

"Peptide and nonpeptide ligands for the nociceptin/orphanin FQ receptor ORL1: research tools and potential therapeutic agents" .

Life Sciences .

73 (6): 663– 78.

doi : 10.1016/S0024-3205(03)00387-4 .

PMC 3848886 .

PMID 12801588 .

Wick MJ, Minnerath SR, Roy S, Ramakrishnan S, Loh HH (September 1995). "Expression of alternate forms of brain opioid 'orphan' receptor mRNA in activated human peripheral blood lymphocytes and lymphocytic cell lines".

Brain Research. Molecular Brain Research .

32 (2): 342– 7.

doi : 10.1016/0169-328X(95)00096-B .

PMID 7500847 .

Meunier JC, Mollereau C, Toll L, Suaudeau C, Moisand C, Alvinerie P, et al. (October 1995).

"Isolation and structure of the endogenous agonist of opioid receptor-like ORL1 receptor" .

Nature .

377 (6549): 532– 5.

Bibcode : 1995Natur.377..532M .

doi : 10.1038/377532a0 .

PMID 7566152 .

S2CID 4326860 .

Yung LY, Joshi SA, Chan RY, Chan JS, Pei G, Wong YH (January 1999). "GalphaL1 (Galpha14) couples the opioid receptor-like1 receptor to stimulation of phospholipase C".

The Journal of Pharmacology and Experimental Therapeutics .

288 (1): 232– 8.

PMID 9862775 .

Feild JA, Foley JJ, Testa TT, Nuthulaganti P, Ellis C, Sarau HM, et al. (October 1999).

"Cloning and characterization of a rabbit ortholog of human Galpha16 and mouse G(alpha)15" .

FEBS Letters .

460 (1): 53– 6.

Bibcode : 1999FEBSL.460...53F .

doi : 10.1016/S0014-5793(99)01317-4 .

PMID 10571060 .

S2CID 86483726 .

Mouledous L, Topham CM, Moisand C, Mollereau C, Meunier JC (March 2000). "Functional inactivation of the nociceptin receptor by alanine substitution of glutamine 286 at the C terminus of transmembrane segment VI: evidence from a site-directed mutagenesis study of the ORL1 receptor transmembrane-binding domain".

Molecular Pharmacology .

57 (3): 495– 502.

doi : 10.1124/mol.57.3.495 .

PMID 10692489 .

Yung LY, Tsim KW, Pei G, Wong YH (2000). "Immunoglobulin G1 Fc fragment-tagged human opioid receptor-like receptor retains the ability to inhibit cAMP accumulation".

Biological Signals and Receptors .

9 (5): 240– 7.

doi : 10.1159/000014645 .

PMID 10965058 .

S2CID 32796564 .

Ito E, Xie G, Maruyama K, Palmer PP (December 2000). "A core-promoter region functions bi-directionally for human opioid-receptor-like gene ORL1 and its 5'-adjacent gene GAIP".

Journal of Molecular Biology .

304 (3): 259– 70.

doi : 10.1006/jmbi.2000.4212 .

PMID 11090272 .

Okada K, Sujaku T, Chuman Y, Nakashima R, Nose T, Costa T, et al. (November 2000). "Highly potent nociceptin analog containing the Arg-Lys triple repeat".

Biochemical and Biophysical Research Communications .

278 (2): 493– 8.

doi : 10.1006/bbrc.2000.3822 .

PMID 11097863 .

Serhan CN, Fierro IM, Chiang N, Pouliot M (March 2001).

"Cutting edge: nociceptin stimulates neutrophil chemotaxis and recruitment: inhibition by aspirin-triggered-15-epi-lipoxin A4" .

Journal of Immunology .

166 (6): 3650– 4.

doi : 10.4049/jimmunol.166.6.3650 .

PMID 11238602 .

Mandyam CD, Thakker DR, Christensen JL, Standifer KM (August 2002). "Orphanin FQ/nociceptin-mediated desensitization of opioid receptor-like 1 receptor and mu opioid receptors involves protein kinase C: a molecular mechanism for heterologous cross-talk".

The Journal of Pharmacology and Experimental Therapeutics .

302 (2): 502– 9.

doi : 10.1124/jpet.102.033159 .

PMID 12130708 .

S2CID 16475164 .

Thakker DR, Standifer KM (September 2002). "Orphanin FQ/nociceptin blocks chronic morphine-induced tyrosine hydroxylase upregulation".

Brain Research. Molecular Brain Research .

105 ( 1– 2): 38– 46.

doi : 10.1016/S0169-328X(02)00390-X .

PMID 12399106 .

Spampinato S, Di Toro R, Alessandri M, Murari G (December 2002).

"Agonist-induced internalization and desensitization of the human nociceptin receptor expressed in CHO cells" .

Cellular and Molecular Life Sciences .

59 (12): 2172– 83.

doi : 10.1007/s000180200016 .

PMC 11146108 .

PMID 12568343 .

S2CID 24462875 .

External links [ edit ] "Opioid Receptors: NOP" .

IUPHAR Database of Receptors and Ion Channels . International Union of Basic and Clinical Pharmacology. Archived from the original on 2016-03-03 . Retrieved 2008-12-09 .

nociceptin+receptor at the U.S. National Library of Medicine Medical Subject Headings (MeSH) Overview of all the structural information available in the PDB for UniProt : P41146 (Nociceptin receptor) at the PDBe-KB .

This article incorporates text from the United States National Library of Medicine , which is in the public domain .

v t e Cell surface receptor : G protein-coupled receptors Class A : Rhodopsin -like Neurotransmitter Adrenergic α1 ( A B D ) α2 ( A B C ) β1 β2 β3 Purinergic Adenosine ( A1 A2A A2B A3 ) P2Y ( 1 2 4 5 6 8 9 10 11 12 13 14 ) Serotonin (all but 5-HT3 ) 5-HT1 ( A B D E F ) 5-HT2 ( A B C ) 5-HT ( 4 5A 6 7 ) Other Acetylcholine ( M1 M2 M3 M4 M5 ) Dopamine D1 D2 D3 D4 D5 GHB receptor Histamine H1 H2 H3 H4 Melatonin ( 1A 1B 1C ) TAAR ( 1 2 5 6 8 9 ) Metabolites and signaling molecules Eicosanoid CysLT ( 1 2 ) LTB4 1 2 FPRL1 OXE Prostaglandin DP ( 1 2 ), EP ( 1 2 3 4 ), FP Prostacyclin Thromboxane Other Bile acid Cannabinoid ( CB1 CB2 , GPR ( 18 55 119 )) EBI2 Estrogen Free fatty acid ( 1 2 3 4 ) Hydroxycarboxylic acids 1 2 3 Lysophosphatidic acid ( 1 2 3 4 5 6 ) Lysophospholipid ( 1 2 3 4 5 6 7 8 ) Oxoglutarate PAF Sphingosine-1-phosphate ( 1 2 3 4 5 ) Succinate Peptide Neuropeptide B/W ( 1 2 ) FF ( 1 2 ) S Y ( 1 2 4 5 ) Neuromedin ( B U ( 1 2 )) Neurotensin ( 1 2 ) Other Anaphylatoxin ( C3a C5a ( 1 2 )) Angiotensin ( 1 2 ) Apelin Bombesin BRS3 GRPR NMBR ) Bradykinin ( B1 B2 ) Chemerin 1 2 Chemokine Cholecystokinin ( A B ) Endothelin A B Formyl peptide ( 1 2 3 ) FSH Galanin ( 1 2 3 ) Gonadotropin-releasing hormone ( 1 2 ) Ghrelin Kisspeptin Luteinizing hormone/choriogonadotropin MAS ( 1 1L D E F G X1 X2 X3 X4 ) Melanocortin ( 1 2 3 4 5 ) MCHR ( 1 2 ) Motilin Opioid ( Delta Kappa Mu Nociceptin & Zeta , but not Sigma ) Orexin ( 1 2 ) Oxytocin Prokineticin ( 1 2 ) Prolactin-releasing peptide Relaxin ( 1 2 3 4 ) Somatostatin ( 1 2 3 4 5 ) Tachykinin ( 1 2 3 ) Thyrotropin Thyrotropin-releasing hormone Urotensin-II Vasopressin ( 1A 1B 2 ) Miscellaneous Taste , bitter TAS2R 1 3 4 5 7 8 9 10 13 14 16 19 20 30 31 38 39 40 41 42 43 45 46 50 60 Vomeronasal receptor type 1 Orphan GPR ( 3 4 6 12 15 17 18 19 20 21 22 26 27 31 32 33 34 35 37 39 42 45 50 52 55 61 62 63 65 68 75 78 82 83 84 85 87 88 101 103 109A 109B 119 120 132 135 137B 139 141 142 146 148 149 150 151 152 153 160 161 162 171 173 174 176 177 182 183 ) Other Adrenomedullin Olfactory Opsin ( 3 4 5 1LW 1MW 1SW RGR RRH ) Protease-activated ( 1 2 3 4 ) SREB ( 1 2 3 ) Class B : Secretin -like Adhesion ADGRB Brain-specific angiogenesis inhibitor 1 2 3 ADGRC Cadherin 1 2 3 ADGRE EMR 1 2 3 CD97 ADGRG 1 2 3 4 5 6 7 ADGRL Latrophilin 1 2 3 ELTD1 Orphan GPR ( 56 64 97 98 110 111 112 113 114 115 116 123 124 125 126 128 133 143 144 155 157 ) Other Calcitonin CALCRL Corticotropin-releasing hormone ( 1 2 ) Glucagon ( GR GIPR GLP1R GLP2R ) Growth-hormone-releasing hormone PACAPR1 GPR Methuselah-like proteins Parathyroid hormone ( 1 2 ) Secretin Vasoactive intestinal peptide ( 1 2 ) Class C : Metabotropic glutamate / pheromone Taste , sweet TAS1R 1 2 3 Vomeronasal receptor , type 2 Other Calcium-sensing receptor GABA B ( 1 2 ) Glutamate receptor ( Metabotropic glutamate ( 1 2 3 4 5 6 7 8 )) GPRC6A GPR ( 156 158 179 ) RAIG ( 1 2 3 4 ) Class F: Frizzled & Smoothened Frizzled Frizzled ( 1 2 3 4 5 6 7 8 9 10 ) Smoothened Smoothened v t e Neuropeptide receptors G protein-coupled receptor Hormone receptors Hypothalamic CRH FSH LHRH TRH Somatostatin Pituitary Vasopressin 1A 1B 2 Oxytocin LHCG TSH Other Atrial natriuretic factor NPR3 Calcitonin Cholecystokinin A B VIP Opioid receptors Delta Kappa Mu Nociceptin Other neuropeptide receptors Angiotensin Bradykinin B1 B2 Tachykinin TACR1 Calcitonin gene-related peptide Galanin GPCR neuropeptide B/W FF S Y Neurotensin Type I cytokine receptor GH Prolactin Enzyme-linked receptor Atrial natriuretic factor NPR1 NPR2 Other Sigma 1 2 v t e Opioid receptor modulators μ-opioid (MOR) Agonists (abridged; full list ) 3-HO-PCP 7-Acetoxymitragynine 7-Hydroxymitragynine ψ-Akuammigine α-Chlornaltrexamine α-Narcotine Acetyldihydrocodeine Acetylfentanyl Acrylfentanyl Adrenorphin (metorphamide) AH-7921 Akuammicine Akuammidine Alfentanil Anileridine Apparicine β-Endorphin BAM-12P BAM-18P BAM-22P Benzhydrocodone Benzylmorphine Bezitramide Biphalin BU08070 Buprenorphine Butorphan Butorphanol Butyrfentanyl BW373U86 Carfentanil Casokefamide Cebranopadol Chloroxymorphamine Codeine DADLE DAMGO (DAGO) Dermorphin Desmetramadol (desmethyltramadol) Desomorphine Deumitragynine Dextromoramide Dextropropoxyphene (propoxyphene) Dezocine Dimenoxadol Dimethylaminopivalophenone Eluxadoline Diamorphine (heroin) Dihydrocodeine Dihydroetorphine Dihydromorphine Dinalbuphine sebacate Diphenoxylate Dipipanone Dynorphin A Embutramide Endomorphin-1 Endomorphin-2 Eseroline Ethylmorphine Etorphine Fentanyl Fluorophen Frakefamide Furanylfentanyl Hemorphin-4 Herkinorin Hodgkinsine Hydrocodone Hydromorphinol Hydromorphone IBNtxA Ketamine Ketobemidone Kratom Laudanosine Lefetamine Leu-enkephalin Levacetylmethadol Levomethorphan Levorphanol Lexanopadol Loperamide Loxicodegol LS-115509 Matrine Meptazinol Met-enkephalin (metenkefalin) Methadone Metkefamide Metopon Mitragynine Mitragynine pseudoindoxyl Morphiceptin Morphine Nalbuphine Naloxone benzoylhydrazone (NalBzOH) Nalmexone Naltalimide Neopine NFEPP Nicocodeine Nicodicodine Nicomorphine Norketamine Nufenoxole Octreotide Oliceridine Oxycodegol Oxymorphone-3-methoxynaltrexonazine (OM-3-MNZ) Oripavine Oxycodone Oxymorphazone Oxymorphonazine Oxymorphone Oxymorphone phenylhydrazone OxyPNPH Papaver somniferum ( opium ) Pentazocine Pericine Pethidine (meperidine) Phenazocine Phencyclidine Piminodine Piritramide PL-017 Prodine Propiram PZM21 Racemethorphan Racemorphan Remifentanil Salsolinol SC-17599 Sinomenine Sufentanil Tapentadol Tetrahydropapaveroline TH-030418 Thebaine Thienorphine Tianeptine Tilidine Tramadol Trimebutine TRIMU 5 TRV734 Tubotaiwine U-47700 Valorphin Viminol Xorphanol Antagonists (3S,4S)-Picenadol 2-(S)-N,N-(R)-Viminol 3CS-nalmefene 4-Caffeoyl-1,5-quinide 4′-Hydroxyflavanone 4',7-Dihydroxyflavone 6β-Naltrexol 6β-Naltrexol-d4 18-MC α-Gliadin β-Chlornaltrexamine β-Funaltrexamine Akuammine Alvimopan AM-251 Apigenin AT-076 Axelopran Bevenopran Catechin Catechin gallate Clocinnamox CTAP CTOP Cyclofoxy Cyprodime Diacetylnalorphine Diprenorphine ECG EGC Epicatechin Eptazocine Gemazocine Ginsenoside R Hyperoside Ibogaine JDTic Levallorphan Lobeline LY-255582 LY-2196044 Methocinnamox Methylnaltrexone Methylsamidorphan chloride Naldemedine Nalmefene Nalodeine (N-allylnorcodeine) Nalorphine Nalorphine dinicotinate Naloxazone Naloxegol Naloxol Naloxonazine Naloxone Naltrexazone Naltrexonazine Naltrexone Naltrindole Naringenin Noribogaine Oxilorphan Pawhuskin A Rimonabant Quadazocine Samidorphan Taxifolin δ-opioid (DOR) Agonists 3CS-nalmefene 6'-GNTI 7-SIOM ADL-5747 (PF-04856881) ADL-5859 Alazocine (SKF-10047) Amoxapine AR-M100390 (ARM390) AZD2327 β-Endorphin BAM-18P Biphalin BU-48 Butorphan Butorphanol BW373U86 Casokefamide Cebranopadol Codeine Cyclazocine DADLE Deltorphin A Deltorphin I Deltorphin II Desmethylclozapine Desmetramadol (desmethyltramadol) Dezocine Diamorphine (heroin) Dihydroetorphine Dihydromorphine DPDPE DPI-221 DPI-3290 DSLET Ethylketazocine Etorphine Fentanyl FIT Fluorophen Hemorphin-4 Hydrocodone Hydromorphone Ibogaine Isomethadone JNJ-20788560 KNT-127 Kratom Laudanosine Leu-enkephalin Levomethorphan Levorphanol Lexanopadol Lofentanil Met-enkephalin (metenkefalin) Metazocine Metkefamide Mitragynine Mitragynine pseudoindoxyl Morphine N-Phenethyl-14-ethoxymetopon Norbuprenorphine NalBzOH Oripavine Oxycodone Oxymorphone Pethidine (meperidine) Proglumide Racemethorphan Racemorphan RWJ-394674 Samidorphan SB-235863 SNC-80 SNC-162 TAN-67 (SB-205,607) TH-030418 Thebaine Thiobromadol (C-8813) Tonazocine Tramadol TRV250 Xorphanol Zenazocine Antagonists 4',7-Dihydroxyflavone 5'-NTII 6β-Naltrexol 6β-Naltrexol-d4 α-Santolol β-Chlornaltrexamine Apigenin AT-076 Axelopran Bevenopran BNTX Catechin Catechin gallate Clocinnamox Diacetylnalorphine Diprenorphine ECG EGC Eluxadoline Epicatechin ICI-154129 ICI-174864 LY-255582 LY-2196044 Methylnaltrexone Methylnaltrindole N-Benzylnaltrindole Nalmefene Nalorphine Naltrexone Naltriben Naltrindole Naloxone Naringenin Noribogaine Pawhuskin A Quadazocine SDM25N SoRI-9409 Taxifolin Thienorphine κ-opioid (KOR) Agonists 3CS-nalmefene 6'-GNTI 8-CAC 18-MC 14-Methoxymetopon β-Chlornaltrexamine β-Funaltrexamine Adrenorphin (metorphamide) Akuammicine Alazocine (SKF-10047) Allomatrine Apadoline Asimadoline BAM-12P BAM-18P BAM-22P Big dynorphin Bremazocine BRL-52537 Butorphan Butorphanol BW373U86 Cebranopadol Ciprefadol CR665 Cyclazocine Cyclorphan Cyprenorphine Desmetramadol (desmethyltramadol) Diamorphine (heroin) Diacetylnalorphine Difelikefalin Dihydroetorphine Dihydromorphine Dinalbuphine sebacate Diprenorphine Dynorphin A Dynorphin B (rimorphin) Eluxadoline Enadoline Eptazocine Erinacine E Ethylketazocine Etorphine Fedotozine Fentanyl Gemazocine GR-89696 GR-103545 Hemorphin-4 Herkinorin HS665 Hydromorphone HZ-2 Ibogaine ICI-199,441 ICI-204,448 Ketamine Ketazocine Laudanosine Leumorphin (dynorphin B-29) Levallorphan Levomethorphan Levorphanol Lexanopadol Lofentanil LPK-26 Lufuradom Matrine MB-1C-OH Menthol Metazocine Metkefamide Mianserin Mirtazapine Morphine Moxazocine MR-2034 N-MPPP Nalbuphine NalBzOH Nalfurafine Nalmefene Nalodeine (N-allylnorcodeine) Nalorphine Naltriben Niravoline Norbuprenorphine Norbuprenorphine-3-glucuronide Noribogaine Norketamine Oripavine Oxa-noribogaine Oxilorphan Oxycodone Pentazocine Pethidine (meperidine) Phenazocine Proxorphan Racemethorphan Racemorphan RB-64 Salvinorin A ( salvia ) Salvinorin B ethoxymethyl ether Salvinorin B methoxymethyl ether Samidorphan Spiradoline (U-62066) TH-030418 Thienorphine Tifluadom Tricyclic antidepressants (e.g., amitriptyline , desipramine , imipramine , nortriptyline ) U-50488 U-54494A U-69593 Xorphanol Antagonists 4′-Hydroxyflavanone 4',7-Dihydroxyflavone 5'-GNTI 6'-GNTI 6β-Naltrexol 6β-Naltrexol-d4 β-Chlornaltrexamine Buprenorphine/samidorphan Amentoflavone ANTI Apigenin Arodyne AT-076 Aticaprant Axelopran AZ-MTAB Binaltorphimine BU09059 Buprenorphine Catechin Catechin gallate CERC-501 (LY-2456302) Clocinnamox CVL-354 Cyclofoxy Dezocine DIPPA EGC ECG Epicatechin Hyperoside JDTic LY-255582 LY-2196044 LY-2444296 LY-2459989 LY-2795050 MeJDTic Methylnaltrexone ML190 ML350 MR-2266 N-Fluoropropyl-JDTic Naloxone Naltrexone Naltrindole Naringenin Navacaprant Norbinaltorphimine Noribogaine Pawhuskin A PF-4455242 RB-64 Quadazocine Taxifolin UPHIT Zyklophin Nociceptin (NOP) Agonists (Arg14,Lys15)Nociceptin ((pF)Phe 4 )Nociceptin(1-13)NH 2 (Phe 1 Ψ(CH 2 -NH)Gly 2 )Nociceptin(1-13)NH 2 Ac-RYYRWK-NH 2 Ac-RYYRIK-NH 2 BU08070 Buprenorphine Cebranopadol Dihydroetorphine Etorphine JNJ-19385899 Levomethorphan Levorphanol Lexanopadol MCOPPB MT-7716 NNC 63-0532 Nociceptin (orphanin FQ) Nociceptin (1-11) Nociceptin (1-13)NH 2 Norbuprenorphine Racemethorphan Racemorphan Ro64-6198 Ro65-6570 SCH-221510 SCH-486757 SR-8993 SR-16435 Sunobinop (S-117957) TH-030418 Antagonists (Nphe 1 )Nociceptin(1-13)NH 2 AT-076 BAN-ORL-24 BTRX-246040 (LY-2940094) J-113397 JTC-801 NalBzOH Nociceptin (1-7) Nocistatin SB-612111 SR-16430 Thienorphine Trap-101 UFP-101 Others Enkephalinase inhibitors : Amastatin BL-2401 Candoxatril D -Phenylalanine Dexecadotril (retorphan) Ecadotril (sinorphan) Kelatorphan Racecadotril (acetorphan) RB-101 RB-120 RB-3007 Opiorphan Selank Semax Spinorphin Thiorphan Tynorphin Ubenimex (bestatin) Propeptides: β-Lipotropin (proendorphin) Prodynorphin Proenkephalin Pronociceptin Proopiomelanocortin (POMC) Others: Kyotorphin (met-enkephalin releaser/degradation stabilizer) Retrieved from " https://en.wikipedia.org/w/index.php?title=Nociceptin_receptor&oldid=1300574420 " Categories : Genes on human chromosome 20 G protein-coupled receptors Hidden categories: Articles with short description Short description matches Wikidata Wikipedia articles incorporating text from the United States National Library of Medicine This page was last edited on 15 July 2025, at 04:31 (UTC) .

Text is available under the Creative Commons Attribution-ShareAlike 4.0 License ;
additional terms may apply. By using this site, you agree to the Terms of Use and Privacy Policy . Wikipedia® is a registered trademark of the Wikimedia Foundation, Inc.

, a non-profit organization.

Privacy policy About Wikipedia Disclaimers Contact Wikipedia Code of Conduct Developers Statistics Cookie statement Mobile view Search Search Toggle the table of contents Nociceptin receptor 3 languages Add topic

